Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension Barman SA; Zhu S; White REVasc Health Risk Manag 2009[]; 5 (ä): 663-71Pulmonary arterial hypertension (PAH) is a devastating disease characterized by progressive elevation of pulmonary arterial pressure and vascular resistance due to pulmonary vasoconstriction and vessel remodeling as well as inflammation. Rho-kinases (ROCKs) are one of the best-described effectors of the small G-protein RhoA, and ROCKs are involved in a variety of cellular functions including muscle cell contraction, proliferation and vascular inflammation through inhibition of myosin light chain phosphatase and activation of downstream mediators. A plethora of evidence in animal models suggests that heightened RhoA/ROCK signaling is important in the pathogenesis of pulmonary hypertension by causing enhanced constriction and remodeling of the pulmonary vasculature. Both animal and clinical studies suggest that ROCK inhibitors are effective for treatment of severe PAH with minimal risk, which supports the premise that ROCKs are important therapeutic targets in pulmonary hypertension and that ROCK inhibitors are a promising new class of drugs for this devastating disease.|Animals[MESH]|Antihypertensive Agents/adverse effects/*therapeutic use[MESH]|Blood Pressure/*drug effects[MESH]|Disease Models, Animal[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Hypertension, Pulmonary/*drug therapy/enzymology/physiopathology[MESH]|Muscle, Smooth, Vascular/*drug effects/enzymology/physiopathology[MESH]|Protein Kinase Inhibitors/adverse effects/*therapeutic use[MESH]|Signal Transduction/*drug effects[MESH]|Treatment Outcome[MESH]|Vascular Resistance/drug effects[MESH]|Vasoconstriction/drug effects[MESH]|rho-Associated Kinases/*antagonists & inhibitors/metabolism[MESH]|rhoA GTP-Binding Protein/*metabolism[MESH] |